Impact of CYP2D64* genotype on progression free survival in tamoxifen breast cancer treatment

Julia Carolin Stingl (formerly Kirchheiner) Institute of Pharmacology of Natural Compounds and Clinical Pharmacology, University Ulm, Germany

Sumit Parmar Institute of Pharmacology of Natural Compounds and Clinical Pharmacology, University Ulm, Germany

Ariana Huber-Wechselberger Institute of Medical and Laboratory Diagnostics, Elisabethinen Hospital Linz, Austria

Alexander Kainz Department of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria

Wilfried Renner Clinical Institute of Medical and Laboratory Diagnostics, Medical University Graz, Austria

Angela Seeringer Institute of Pharmacology of Natural Compounds and Clinical Pharmacology, University Ulm, Germany

Jürgen Brockmöller Department of Clinical Pharmacology, University Medical Center, University Göttingen, Germany

Uwe Langsenlehner Internal Outpatient Department, Graz, Austria

Peter Krippl Department of Internal Medicine, General Hospital Fürstenfeld, Austria

Elisabeth Haschke-Becher Institute of Medical and Laboratory Diagnostics, Elisabethinen Hospital Linz, AustriaCorrespondence[email protected]

Your download is now in progress and you may close this window